Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Illumina (ILMN)

Illumina Reports Q3 2026 Financial Results and Raises Full-Year Guidance

Positive Impact 4 of 5 guidance

Illumina announced third-quarter 2026 financial results with reported revenue of $1.13 billion, representing a 4.2% increase compared to the prior-year period. Driven by healthy clinical demand and NovaSeq X placements, the company raised its full-year 2026 total revenue guidance to $4.64-$4.66 billion and non-GAAP diluted EPS guidance to $5.40-$5.45.

Key points

  • Reported revenue for Q3 2026 was $1.13 billion, up 4.2% from Q3 2025.
  • GAAP diluted EPS for Q3 2026 was $1.43, compared to $0.98 in Q3 2025.
  • Free cash flow for Q3 2026 reached $378 million, compared to $253 million in the prior-year period.
  • Full-year 2026 revenue guidance was raised to $4.64-$4.66 billion, up from the previous range.

The filing

CompanyIllumina (ILMN)
Form8-K, current report
Filed with the SECOct 29, 2026, 4:07 PM ET
Accession number0001110803-26-000202

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Oct 29, 2026, 6:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.